Similarly, some studies have found CXCL2 to have a pro-tumorigenic role in breast cancer, but others have found that it may promote anti-tumor immunity by potentiating responses to PD-1 blockade and increasing the infiltration of anti-tumorigenic N1 neutrophils in TNBC [48]. This evidence concerns the gene PDCD1 and breast carcinoma.